Per-Henrik Zahl (born 1961), MD, PhD in biostatistics, statistician at the Division of Mental and Physical Health, Norwegian Institute of Public Health. He has published a number of articles about mammography screening and breast cancer mortality.
The author has completed the ICMJE form and declares no conflicts of interest.
Øyvind Holme (born1970), PhD and specialist in general internal medicine and digestive diseases at Sørlandet Hospital, Kristiansand, and the Clinical Effectiveness Research Group, Institute of Health and Society, Faculty of Medicine, University of Oslo.
The author has completed the ICMJE form and declares no conflicts of interest.
Magnus Løberg (born 1979), MD, PhD and post-doctoral fellow at the Clinical Effectiveness Research Group, Institute of Health and Society, Faculty of Medicine, University of Oslo, at the Department of Transplantation Medicine, Oslo University Hospital and at the K.G. Jebsen Centre for Colorectal Cancer Research, Oslo.
The author has completed the ICMJE form and declares no conflicts of interest.
()
1.
Research-based evaluation of the Norwegian Breast Cancer Screening Program. Oslo: The Research Council of Norway, 2015.
Zahl P-H, Jørgensen KJ, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013; 109: 2014 – 9. [PubMed] [CrossRef]
5.
Suhrke P, Zahl P-H. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study. Cancer Med 2015; 4: 1303 – 8. [PubMed] [CrossRef]
6.
Zahl PH, Mæhlen J. Bias in observational studies of the association between menopausal hormone therapy and breast cancer. PLoS One 2015; 10: e0124076. [PubMed] [CrossRef]
7.
Ioannidis JPD. Contradicted and initially stronger effects in highly cited clinical research. JAMA 2005; 294: 218 – 28. [PubMed] [CrossRef]
8.
Banks E, Reeves G, Beral V et al. Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. BMJ 2004; 329: 477 – 82. [PubMed] [CrossRef]
9.
Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. (review). Cochrane Database Syst Rev 2013; 6: CD001877. [PubMed]
10.
Autier P, Boniol M, Middleton R et al. Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol 2011; 22: 1726 – 35. [PubMed] [CrossRef]
11.
Lousdal ML, Kristiansen IS, Møller B et al. Effect of organised mammography screening on stage-specific incidence in Norway: population study. Br J Cancer 2016; 114: 590 – 6. [PubMed] [CrossRef]
12.
Carter JL, Coletti RJ, Harris RP. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ 2015; 350: g7773. [PubMed] [CrossRef]
13.
Zahl PH, Strand BH, Mæhlen J. Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. BMJ 2004; 328: 921 – 4. [PubMed] [CrossRef]
14.
Aalen OO. Nonparametric inference for a family of counting processes. Ann Stat 1978; 6: 701 – 26 . [CrossRef]
15.
Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008; 168: 2311 – 6. [PubMed] [CrossRef]
Weedon-Fekjær H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: population study. BMJ 2014; 348: g3701. [PubMed] [CrossRef]
18.
Kalager M, Zelen M, Langmark F et al. Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med 2010; 363: 1203 – 10. [PubMed] [CrossRef]
19.
Olsen AH, Lynge E, Njor SH et al. Breast cancer mortality in Norway after the introduction of mammography screening. Int J Cancer 2013; 132: 208 – 14. [PubMed] [CrossRef]
20.
Autier P, Boniol M, Gavin A et al. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ 2011; 343: d4411. [PubMed] [CrossRef]
21.
Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378: 771 – 84. [PubMed] [CrossRef]
This article was published more than 12 months ago and we have therefore closed it for new comments.
Tre dager før vår artikkel om selvmotsigelser i evalueringen av mammografiscreening i Norge ble publisert i Tidsskriftet (1) publiserte tidsskriftet New England Journal of Medicine (2) en artikkel som konkluderte stikk motsatt av hva Norges forskningsråd…
If you do not see the PDF file or want to save the file, you can right-click on the PDF icon. Select «Save target / file as ...» and then retrieve the PDF file in, for example, Acrobat Reader.
Mammografiscreening evaluert med sunn fornuft
09.11.2016Tre dager før vår artikkel om selvmotsigelser i evalueringen av mammografiscreening i Norge ble publisert i Tidsskriftet (1) publiserte tidsskriftet New England Journal of Medicine (2) en artikkel som konkluderte stikk motsatt av hva Norges forskningsråd…